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Abstract—The aim of this paper is to introduce the recent 
research and commercial developments in minimally and non-
invasive blood glucose monitoring techniques.  
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I. INTRODUCTION 
Diabetes is one of the largest global health emergencies of 
the 21st century [1]. More than 1 in 11 adults (415 million) 
were found to have diabetes in 2015 and this number is rapidly 
rising, being estimated to reach almost 1 in 10 adults (642 
million) by 2040. At least 673 billion USD in health 
expenditure were spent on the care of diabetes related 
complications, including direct and indirect costs. In the United 
Kingdom, 17% of the total spending by the National Health 
Service is estimated to be spent on diabetes in 2035/2036 
[2][3]. There are significant amount of ongoing researches but 
there is no known cure for diabetes yet. 
For people with diabetes, the most important requirement is 
a tight control of the blood glucose (BG) level to minimize the 
dwelling time in high (>11.1 mmol/L) or low (<3.9 mmol/L) 
BG levels. The most effective method to achieve tight control 
is to self-monitor the BG levels as frequent as possible. 
Fingerprick test by using test strips and a glucose meter is the 
most common and widely available method for its reasonable 
accuracy and precision, convenience, and its ability to provide 
real-time plasma glucose levels on demand. Wide range of 
commercial glucose meters and reagent test strips are available 
including Abbott’s Freestyle line, Ascensia Diabetes Care’s 
(formerly Bayer) Contour line, GlucoRX’s Nexus line, 
LifeScan’s OneTouch line, and Roche’s Accu-Check line, to 
name a few. However, a number of factors discourage the use 
of this method, especially the pain due to repeated finger-prick 
with lancets to draw blood sample, fear of infection during the 
pricking process, cost of test accessories, and the invasiveness 
to their daily life. One of the critical disadvantages of the 
fingerprick test is that it is only able to provide a discrete 
snapshot of the continuous change of BG levels during the day. 
Therefore one might miss important hyperglycemic and 
hypoglycemic events between the discrete fingerprick tests.  
To overcome this issue, continuous glucose monitoring 
(CGM) methods have been developed. The most common 
method is to have a flexible needle placed under the skin with a 
data transmitting device sitting on the skin, which continuously 
monitors interstitial fluid (ISF) glucose levels. Among several 
techniques, an enzyme-based electrochemical sensing method 
is adopted for commercial products for its specificity and 
decent accuracy, and small footprint required. This technique 
has contributed in improving the quality of life of people with 
diabetes by reducing the required number of fingerprick tests 
and providing the continuous trace of fluctuation of glucose 
levels. With the rapid development of circuit integration 
technologies, CGMs have made a great leap and are becoming 
more and more popular. Still, the flexible subcuraneous needle 
has to be inserted into the skin by an invasive guide needle and 
therefore same disadvantages still exist regarding the 
invasiveness of the technique, including the pain and fear of 
infection and the replacement of the sensor every few weeks. 
Therefore the demand and expection for a truly non-invasive 
blood glucose monitor is growing higher and higher.  
II. RESEARCH PUBLICATIONS 
A number of minimally invasive and purely non-invasive 
blood glucose monitoring devices have been reported based on 
a wide range of interesting technologies [4]-[7]. In [8], 
ultrasound was facilitated to enhance the outward transport of 
glucose from ISF through skin to overcome the fundamental 
problem of obtaining sufficient amount of samples in a 
transdermal approach (sonophoresis). A small implantable 
fluorescence-based sensor combined with a body-worn data 
transmitter was proposed in [9] to increase the sensor lifetime 
up to 6 months comparing to a few weeks’ lifetime of typical 
subcutaneous sensors. A watch-type transdermal sensor using 
microneedles to extract ISF glucose through skin [10], an 
ultrasound and multi-sensor-based ear-clip type non-invasive 
sensor for discrete measurement [11], a contact-lens-type 
noninvasive sensor measuring glucose concentration in tears 
[12], an occlusion spectroscopy-based sensor measuring blood 
flow [13], and electrochemical subcutaneous continuous 
monitoring sensors [14] have been reported. A sensor based on 
the combination of impedance (10 to 76 kHz range) and multi-
wavelength (850nm, 950nm, 1300nm) near infra-red (NIR) 
spectroscopy with a dedicated integrated circuit [15] and a 
technique measuring the refraction of visible laser light to 
overcome the signal to noise ratio issue related to NIR 
spectroscopy [16] were also reported. Wearable sensors 
capable of measuring glucose concentration through saliva and 
sweat [17][18], and a benchtop system capable of estimating 
glucose level through breath have been published [19][20]. 
In the RF and microwave area, the resonant and non-
resonant near-field monitoring technique has been widely used 
for its non-invasive characteristic and high sensitivity. A 
broadband coplanar waveguide sensor with the combination of 
microfluidic system was proposed in [21] to evaluate the This work was supported by the Wellcome Trust [WT096848MA]; the Ser Cymru II Fellowship[80762CU083]. 
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relative effective permittivity of human umbilical vein 
endothelial cells. An open-ended spiral-shaped microstrip line 
sensor was proposed for non-invasive BG measurement but 
with limited dataset from 5 subjects [22]. A reflection and 
transmission based broadband measurement techniques using 
microstrip line [23] and microstrip patch/slot antenna-based 
sensor [24] can be found, but without human clinical trial 
results. Millimeter-wave waveguide transmission measurement 
system and its clinical trial results on rats [25] have been 
reported using microwave techniques. The basis of these is that 
the complex dielectric constant changes with the presence and 
fluctuation of blood glucose concentration in the water/glucose 
system [26][27]. Microwave non-invasive blood glucose 
monitoring sensors based on split-ring resonators have also 
been reported with human clinical trial results, showing its 
potential as a candidate method [28][29].  
 
Fig. 1. Human clinical trial results of split-ring resonator sensor over 24 test 
subjects in Clarke Error Grid, from [29]. 
III. COMMERCIAL DEVELOPMENTS 
There is no truly non-invasive and continuous blood 
glucose monitoring sensor availabe in the self-monitoring of 
BG market yet. It is extremely difficult challenge to be able to 
detect only a small fluctuation in BG concentration through a 
very lossy human tissue, with endogenic chemical interference, 
with physiological variation between subjects, during a normal 
daily life (environmental variation and movement) to name a 
few. On top of that, accuracy and precision requirement by the 
medical regulation and standard (e.g., ISO:15197:2013) is ever 
increasing. In its current version, ISO:15197 requires that 95% 
of BG test results should meet the following key requirements:  
- Within ± 15 mg/dL (or 0.83 mmol/L) of laboratory results 
at concentrations under 100 mg/dL (or 5.6 mmol/L) 
- Within ± 15% of laboratory results at concentrations of 
100 mg/dL (or 5.6 mmol/L) or more.  
- For type 1 diabetes, 99% of readings must fall within 
zones A and B of the Consensus Error Grid 
However there are several candidates that provide near-non-
invasive performance, and some examples are now discussed.   
GlucoTrack model DF-F (by Integrity Applications) is a 
CE-Mark approved device, which consists of an ear clip type 
sensor and a main display unit. It is known to use ultrasound, 
electromagnetic and temperature measurements with a unique 
algorithm to weight each measurement and calculate the 
weighted average of the three readings [11]. Technically this 
device is truly non-invasive but in their current version only 
discrete readings are available and the accuracy is not as good 
as enzyme-based subcutaneous sensors. The ear clip must be 
replaced every 6 months for reliable measurements. Clinical 
trial results show that 97.3% of the readings fall within Zone A 
and B in the Clarke Error Grid [11].  
SugarBEAT (by Nemaura Medical) is a patch type sensor, 
known to use the technique called reverse iontophoresis [30]. It 
passes a mild, non-perceptible electric current across the skin 
to draw a small amount of glucose molecules from the ISF into 
a patch placed on the skin. The recent clinical trial consisted of 
81 paired data points, with a single finger prick calibration, and 
glucose range between 70-400 mg/dl. The results indicated a 
mean absolute relative difference (MARD) of 14.05%, and 
75% of the data in Zone A, and over 98% of the data in Zones 
A and B of the Clarke Error grid. The patch lasts one day and 
needs one finger prick calibration a day. The device is aimed to 
be launched in 2017.  
NovioSense is a small and flexible spring like device 
measuring less than 2 cm in length and 1.5mm in diameter 
[31]. The whole device is coated with a soft hydrogel layer. 
The flexible form factor allows the device to bend to conform 
to the surface of the lower eye lid where the sensor is placed. 
This device uses a glucose oxidase electrochemical sensor 
attached to a hollow coil coated in hydrophilic gel allowing the 
sensor to follow the shape of the eye. It utilizes state of the art 
low-power and highly sensitive ASIC technology developed by 
the Fraunhofer Institute of Microelectronic Circuits and 
Systems together with NovioSense. The device can measure 
minute changes in glucose levels in the tears that are 
representative of blood glucose levels. Through animal studies, 
92% of data were in Zone A+B region of the Clarke Error 
Grid. The device is aimed to be launched in 2018.  
One critical challenge of measuring glucose concentration 
through ISF is the dispersion delay. Dispersion delay is the 
time for plasma glucose to disperse from blood vessel to ISF. 
This can vary from 5 to 45 minutes between subjects, and can 
even vary for a specific subject on a different day. Tear, saliva, 
or sweat have even longer dispersion delay than ISF, so they 
are not suitable for type 1 diabetes.  
The Eversense Sensor is designed to be implanted 
subcutaneously in the upper arm [32]. No part of the sensor 
protrudes out of the skin surface. Encased in a biocompatible 
material, the sensor utilizes a patented fluorescent, glucose 
indicating polymer technology to measure glucose in the ISF. 
The measurement is then relayed to the smart transmitter. The 
measurement and display of glucose values is done 
automatically, without the need for user intervention. 
Senseonics’ Eversense CGM has shown exceptional results in 
a clinical study: 8.8%. The PRECISE II clinical study enrolled 
90 adults with diabetes over 90 days of continuous glucose 
sensor wear. The study collected over 16,000 comparative data 
points with over 2 million glucose readings. Although simple, 
this device requires a surgical operation.  
The FreeStyle Libre (by Abbott) is a flash glucose 
monitoring system which allows people to test their BG levels 
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by scanning a subcutaneous sensor on their arm measuring ISF 
glucose rather than taking finger-prick blood glucose tests [33]. 
The system is able to provide graphical trends of sugar levels 
which provides much more data than blood glucose tests. 
Unlike CGMs, the Libre is not able to alert the user of high or 
low blood sugar until the user actively scans. However, the 
trendline shows whether sugar levels are heading up or down, 
and how quickly, which alarms the user  of the onset of 
hypoglycemia. The FreeStyle Libre system has a proven 
accuracy of 11.4% MARD compared to a reference BG 
concentration. It is clinically proven to be accurate, stable and 
consistent over 14 days without the need for finger prick 
calibration. To be able to insert the flexible subcutaneous 
needle, an insertion device with a big guide needle must be 
used.  
IV. CONCLUSION 
Diabetes prevalence is on the rapid rise worldwide and is a 
crisis facing 21st century society. Therefore, the self-
monitoring blood glucose device market is exponentially 
growing. A variety of techniques to achieve minimally invasive 
and truly non-invasive blood glucose monitoring have been 
reviewed, including RF, microwave, mm-wave, and even optic 
wavelength, with highly promising results.  
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